Utility of a microRNA panel in diagnosis and prognosis of hepatitis C–associated hepatocellular carcinoma
Laboratory Medicine · 2024
DOI: 10.1093/labmed/lmad081 ↗Kurz gefasst
Fachartikel in der Zeitschrift Laboratory Medicine, 2024. Verfasst von Abeer Ahmed ALrefai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical Biochemistry and Molecular Biology Department. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, MicroRNAs. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Background
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and the leading cause of cancer mortality. Various studies have linked dysregulated microRNA expression to liver cancers, but those related to viral hepatitis–related HCC are limited.
Methods
We investigated the diagnostic and prognostic roles of circulating miR-331-3p, miR-23b-3p, and miR-3194-5p in EDTA-treated blood samples of 50 hepatitis C virus (HCV) HCC patients, 50 HCV cirrhotic patients, and 50 healthy controls using quantitative real-time polymerase chain reaction.
Results
We found that miR-23b-3p and miR-3194-5p were significantly downregulated, whereas miR-331-3p was upregulated in HCC patients compared with controls. Also, these miRNAs were significantly dysregulated in HCC compared with cirrhotic patients. For the diagnosis of HCC, miR-331-3p and the combined miRNAs panel had the highest area under the curve (AUC), followed by miR-3194-5p. The highest AUC for differentiating metastatic from nonmetastatic patients was shown by miR-331-3p and the combined miRNAs panel, followed by miR-23b-3p. Dysregulation of miRNAs was associated with poor clinicopathological manifestations. Finally, miR-331-3P was found to be an independent risk factor for metastatic lesions in HCC.
Conclusion
Overall, the assessed miR-331-3p, miR-23b-3p, and miR-3194-5p were significantly associated with poor clinicopathological features of HCC and could be used to discriminate HCV-related HCC patients from cirrhosis and differentiating metastatic from nonmetastatic patients, primarily miR-331-3p along with combined miRNAs. Moreover, miR-331-3p was found to be an independent factor for metastatic lesions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Biochemistry and Molecular Biology Department.
- Biochemistry Department, Faculty of Medicine, UQU, Mecca, Kingdom of Saudi Arabia.
- Internal Medicine Department, National Liver Institute.
- Department of Public Health and Community Medicine, Faculty of Medicine, Menoufia University, Shibin El Kom, Egypt.
- Medical Biochemistry Department, Najran University, Najran, Kingdom of Saudi Arabia.
ORCID-Profile: Abeer Ahmed ALrefai, Sara Kamal Rizk, Ahmed Kamal Khamis, Zeinab A Kasemy, Mona Salah Eldin Habieb
Zitieren
APA
ALrefai, A. A., Rizk, S. K., Khamis, A. K., Kasemy, Z. A., & Habieb, M. S. E. (2024). Utility of a microRNA panel in diagnosis and prognosis of hepatitis C–associated hepatocellular carcinoma. Laboratory Medicine. https://doi.org/10.1093/labmed/lmad081
Vancouver
ALrefai AA, Rizk SK, Khamis AK, Kasemy ZA, Habieb MSE. Utility of a microRNA panel in diagnosis and prognosis of hepatitis C–associated hepatocellular carcinoma. Laboratory Medicine. 2024. doi:10.1093/labmed/lmad081
BibTeX
@article{ALrefai2024,
author = {ALrefai, Abeer Ahmed and Rizk, Sara Kamal and Khamis, Ahmed Kamal and Kasemy, Zeinab A and Habieb, Mona Salah Eldin},
title = {Utility of a microRNA panel in diagnosis and prognosis of hepatitis C–associated hepatocellular carcinoma},
journal = {Laboratory Medicine},
year = {2024},
doi = {10.1093/labmed/lmad081}
}
EUVIMED